Harry Schrager, MD
Internal Medicine · Newton, MANPI 1871540666
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $400 of the $562 with a category attached, or 71.2%. Pfizer accounts for 71.2% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $400, 2.8 times the $143 reported in 2019.
Across 4 payments — averaging $140.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$400
- AbbVie$118
- Melinta Therapeutics, LLC$25
- Bavarian Nordic A/s$19
Across 187 payments — averaging $3103.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dompe Farmaceutici S.p.a.$281K
- Boehringer Ingelheim$151K
- Gilead$127K
- AstraZeneca$22K
What the payments were for
- Consulting fees$40071%
- Food & beverage$16229%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 1 | $400 |
| AbbVie | 1 | $118 |
| Melinta Therapeutics, LLC | 1 | $25 |
| Bavarian Nordic A/s | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVYCAZ$118
How this compares
$562 in reported general payments places this provider in the 80th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl | 122 | $7,884 |
| Typhim ViTyphoid Vi Polysacch Vaccine | 15 | $4,284 |
| Cephalexin | 21 | $1,157 |
| Doxycycline Monohydrate | 25 | $593 |
| Azithromycin | 161 | $503 |
| Oseltamivir Phosphate | 12 | $441 |
| Cefadroxil | 14 | $247 |
| Clindamycin Hcl | 14 | $166 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Newton
- David SchenkeinBoston$5M
- Alan GarberCambridge$4.9M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Sandra RichmanBrookline$1.4M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.